Third Harmonic Bio, Inc.
THRD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for THRD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2025.
Tracking 2 pipeline candidates · 2 clinical trials for Third Harmonic Bio, Inc..
Similar companies
Run Third Harmonic Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Third Harmonic Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
60.8 months
D/E 0.03
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Third Harmonic Bio, Inc.'s lead drug candidate?
Third Harmonic Bio, Inc.'s most advanced tracked candidate is thb001 (Phase 1) for chronic inducible urticaria.
Who is the CEO of Third Harmonic Bio, Inc.?
Natalie Holles is the chief executive officer of Third Harmonic Bio, Inc. (THRD).
What therapeutic areas does Third Harmonic Bio, Inc. focus on?
Third Harmonic Bio, Inc. develops therapies across Healthy/Normal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.